PHPekko Hujanen

Pekko Hujanen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pekko Hujanen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of delayed appointments on treatment outcomes in neovascular macular degeneration

    by Petri Purola, Pekko Hujanen, Hannu Uusitalo, Hannele Uusitalo‐Järvinen

    Purpose: To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD). Methods: This single‐centre retrospective study included a cohort of 3831 treatment‐naïve nAMD patients who were treated with bevacizumab monotherapy using a pro re nata protocol between 2008 and 2023, comprising a total of 79 545 visits. Visual acuity (VA) was measured at the time of diagnosis and during follow‐up visits and was converted into Early Treatment Diabetic Retinopathy Study letters. One eye per patient was included in the analysis. Delayed visits were categorised as >6 weeks and ≤8 weeks, >8 weeks and ≤ 10 weeks and >10 weeks. Results: After an initial stabilisation in VA during the first treatment year, VA started to decline. The proportion of visits delayed >6 weeks varied between 24% and 36% per treatment year, with delays being more common during the early years of the study when the new therapies were introduced. In general, the decline in VA was more severe with a higher number and longer duration of delayed visits. Conclusions: Delays in anti‐VEGF injections are common and strongly associated with vision loss. Therefore, it is important to improve patient awareness and compliance. Use of new longer‐acting therapies may support this process.

  • Open Access

    Prototype master protocol for benchmarking of real‐world follow‐up data in glaucoma

    by Pekko Hujanen, Anja Tuulonen, Sanna Leinonen, Kristian Vepsäläinen, Gauti Jóhannesson, Anu Vaajanen, Eemil Lehtonen, Hannele Uusitalo‐Jarvinen

    Purpose: The purpose of this study was to create a prototype master protocol for benchmarking glaucoma real‐world data (RWD). Benchmarking is part of the digital innovation strategy of the Finnish aces‐rwm ecosystem (automation of care and evaluation of the system with real‐world monitoring).Methods: We collected glaucoma RWD in 2012–17 at Tampere University Hospital (Tays) and compared them to six published RWD sets (one in Sweden and five in England). Visual field (VF) data at Tays were retrieved from the perimeter, and clinical RWD were collected manually. At baseline, VF data were available in 2511 of 4121 glaucoma patients (61%), of whom 1413 patients (56%) had 5 years of VF follow‐up by 2017 (34% of all 4121 patients). Mean deviation (MD) data were analysed in multiple ways, considering also age and intraocular pressure (IOP).Results: In most data sets, higher age was related to faster progression. At Tays, the distributions of progression rates were similar in better and worse eyes. The proportions of eyes at Tays with the medium rate of MD progression (17% for 0.5–1.5 dB/year) and the fast rate (6% for >1.5 dB/year) were similar to the published RWD trial in England. The published datasets show significant variability in how their findings were reported.Conclusions: This study represents a first step toward the development of a master protocol for real‐world benchmarking of glaucoma care. Further refinement of the protocol will encourage and require national and international collaboration in order to produce comprehensive and comparable real‐world EHR data sets.


  • Open Access

    Immediate sequential bilateral cataract surgery: a 13-year real-life report of 56 700 cataract operations

    by Pekko Hujanen, Anu Vaajanen, Tuukka Felin, Eemil Lehtonen, Ulla Syvänen, Heini Huhtala, Mika Helminen, Harri Sintonen, Anja Tuulonen, Hannele Uusitalo-Järvinen

    Background/aims To assess the frequency of immediate sequential bilateral cataract surgery (ISBCS) and endophthalmitis during 13-year period in Tays Eye Centre, Tampere University Hospital, Tampere, Finland. Methods All cataract surgeries performed between 1 January 2008 and 31 December 2020, and all endophthalmitis cases during the same period were searched from electronic patient records. Numbers and frequencies of ISBCS, and complications, including endophthalmitis and vitreous loss, were recorded and compared with unilateral operations. Results The study included 56 700 cataract surgeries in 34 797 patients of whom 39% (n=13 445) had ISBCS. The median age of the patients was 75 (IQR 68–80, range 0.08–99) years at the time of surgery. The proportion of ISBCS patients increased from 4.2% in 2008 to 46% in 2020. Vitreous loss occurred in 480 (0.9%) of cataract surgeries. There were no postoperative endophthalmitis after cataract surgery (n=0) during the 13-year period. Conclusion The proportion of patients undergoing ISBCS increased from 4.2% in 2008 to 46% in 2020. No endophthalmitis were found to be associated with ISBCS.


  • Open Access

    Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting

    by Maria Kataja, Pekko Hujanen, Heini Huhtala, Kai Kaarniranta, Anja Tuulonen, Hannele Uusitalo-Jarvinen

    Aims To evaluate outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (nAMD) in the real-life setting and to compare incidence of ocular serious adverse events (SAE) after injections administered by nurses and physicians. Methods Retrospective, single-centre study. Medical records of patients receiving anti-VEGF treatment for nAMD between 2008 and 2013 with three-loading-dose regimen were evaluated. Outcome measures were baseline visual acuity (VA), change in VA, number of intravitreal injections, incidence of ocular SAE and patients’ baseline characteristics affecting VA change. In addition, the number of injections per 1000 citizens living in the serving area and per individuals over 65 years old were estimated. Results 1349 eyes in 1117 patients received a total of 11 562 intravitreal anti-VEGF injections. Twenty-one per cent of patients received treatment for both eyes. The mean baseline Snellen VA was 0.32. The mean change of VA from baseline was +2, +2 and ±0 Early Treatment Diabetic Retinopathy Study letters and the mean numbers of injections were 5.7, 4.7 and 4.9 at years 1, 2 and 3, respectively. There was a negative correlation between baseline VA and change of VA. Incidence of endophthalmitis was 0.086%. No difference in the incidence of ocular SAE was identified between injections given by nurses or by physicians. The number of intravitreal injections per all citizens was 9 per 1000 inhabitants and 45 per 1000 inhabitants over 65 years. Conclusion The VA was maintained at the baseline level (±0 letters) with the mean of 15.3 anti-VEGF injections in real-world clinical practice during 3-year follow-up.


  • The use of dopamine agonists in newly diagnosed Parkinson's disease patients has changed

    by H. Kuusisto, P. Hujanen, T. Mattila, T. Luukkaala, T. Keränen